Top Insights
Health
globalreutersSeptember 29, 20241 Mins read
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
globalreutersSeptember 29, 20241 Mins read 
Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA-approved indication for the blockbuster drug.
The post Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD appeared first on MedCity News.
Leave a comment